Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Forge Therapeutics is a biotechnology company developing novel medicines by combining bioinorganic with medicinal chemistry to target metalloenzymes. Metalloenzymes make up over 30% of all known enzymes in nature and are critically important for a wide range of biochemical processes and biological catalysis. Forge has developed a fundamentally new approach for the discovery of metalloenzyme inhibitors by focusing first on the ...
Forge Therapeutics is a biotechnology company developing novel medicines by combining bioinorganic with medicinal chemistry to target metalloenzymes. Metalloenzymes make up over 30% of all known enzymes in nature and are critically important for a wide range of biochemical processes and biological catalysis. Forge has developed a fundamentally new approach for the discovery of metalloenzyme inhibitors by focusing first on the metal in the enzyme active site. Forge was founded based on work that emerged over the last 15 years from the laboratory of Professor Seth Cohen at the University of California San Diego.

List your booth number for exhibitions, ask us